IN
INMB.US INmune Bio Inc
- Market cap
- USD 32.5M
- P/E
- -
- P/B
- 1.79x
- ROE
- -84.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is INMB.US undervalued?
Graham numberThe Graham number of INmune Bio Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
INmune Bio Inc fundamental analysis
No fundamental analysis for INmune Bio Inc yet.
INmune Bio Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About INmune Bio Inc
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II fo…
Full company profileINmune Bio Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
INmune Bio Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 77.7M | 10.9K | 181K | 374K | 155K | 14.0K | 50.0K | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 77.7M | 10.9K | 181K | 374K | 155K | 14.0K | 50.0K | - |
| Operating Income | -227K | -981K | -12.4M | -7.76M | -12.2M | -29.2M | -26.0M | -29.7M | -42.6M | -30.9M | -16.4M |
| EBITDA | -49.5K | 150K | -12.4M | -7.68M | -12.2M | -30.3M | -27.3M | -267K | -41.5M | -45.8M | -15.0M |
| Net Income | -277K | -831K | -12.4M | -7.68M | -12.1M | -30.3M | -28.6M | -30.0M | -42.1M | -45.9M | -15.2M |
| EPS | -0.05 | -0.07 | -1.11 | -0.75 | -1.01 | -1.88 | -1.60 | -1.67 | -2.11 | -1.73 | -0.55 |
| Balance Sheet | |||||||||||
| Total Assets | 452K | 18.4M | 17.4M | 24.5M | 40.7M | 99.9M | 81.8M | 57.0M | 39.6M | 32.4M | 21.5M |
| Total Liabilities | 601K | 310K | 824K | 861K | 1.90M | 19.7M | 21.7M | 18.9M | 7.47M | 8.83M | 3.44M |
| Shareholders' Equity | -149K | 18.1M | 16.5M | 23.6M | 38.8M | 80.2M | 60.1M | 38.1M | 32.1M | 23.5M | 18.1M |
| Cash & Short-term Investments | 142K | 1.37M | 186K | 7.00M | 22.0M | 74.8M | 52.2M | 35.8M | 20.9M | 24.8M | 16.3M |
| Total Debt | 350K | - | - | 168K | 160K | 15.2M | 15.3M | 10.4M | 384K | 1.03M | 1.21M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -317K | -762K | -2.06M | -5.38M | -8.94M | -28.5M | -22.7M | -12.0M | -33.4M | -22.6M | -13.3M |
| Capital Expenditure | 0.00 | 100K | 0.00 | 0.00 | 4.00 | 15.0M | 0.00 | 0.00 | 0.00 | 1.04M | 1.15M |
| Free Cash Flow | -317K | -862K | -2.06M | -5.38M | -8.94M | -43.5M | -22.7M | -12.0M | -33.4M | -23.6M | -13.3M |
| Ratios | |||||||||||
| ROE | - | -4.6% | -75.2% | -32.5% | -31.2% | -37.8% | -47.7% | -78.7% | -131.1% | -195.3% | -84.1% |
| ROA | -61.3% | -4.5% | -71.6% | -31.4% | -29.8% | -30.4% | -35.0% | -52.6% | -106.4% | -142.0% | -70.7% |
| Net Profit Margin | - | - | - | -9.9% | -110,838.8% | -16,762.4% | -7,659.6% | -19,360.0% | -300,585.7% | -91,866.0% | - |
| Debt to Equity | - | - | - | 0.01x | 0.00x | 0.19x | 0.25x | 0.27x | 0.01x | 0.04x | 0.07x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
INmune Bio Inc dividends
INmune Bio Inc has not paid dividends in the last 9 fiscal years.
Who owns INmune Bio Inc
- Insiders 9.71%
- Institutions 16.35%
- Public & others 73.94%
- Shares outstanding 31.0M
- Free float 27.9M
Top funds holding INMB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 490K | 1.58% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 117K | 0.38% | -31.27% | Sep 2026 |
| Abante Quant Value FI | 80.3K | 0.26% | 0.00% | Aug 2026 |
| iShares Micro-Cap ETF | 74.1K | 0.24% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 29.2K | 0.09% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 26.6K | 0.09% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 20.2K | 0.07% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 13.5K | 0.04% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 12.0K | 0.04% | 0.00% | Aug 2026 |
| DFA US Micro Cap I | 5.79K | 0.02% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 5.58K | 0.02% | 0.00% | Sep 2026 |
| Dimensional US Small Cap ETF | 4.27K | 0.01% | 0.00% | Oct 2026 |
| Dimensional Global Core Equity USD Acc | 3.00K | 0.01% | -0.30% | Sep 2026 |
Top institutions holding INMB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 706K | 2.28% | +2.83% | Jun 2026 |
| AQR Capital Management LLC | 662K | 2.14% | +144.98% | Jun 2026 |
| BlackRock Inc | 312K | 1.01% | -73.90% | Jun 2026 |
| Renaissance Technologies Corp | 298K | 0.96% | +903.37% | Sep 2026 |
| Geode Capital Management, LLC | 190K | 0.61% | -61.57% | Jun 2026 |
| The Goldman Sachs Group Inc | 185K | 0.60% | -20.01% | Jun 2026 |
| Millennium Management LLC | 160K | 0.52% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 158K | 0.51% | -18.49% | Jun 2026 |
| Jane Street Group LLC | 134K | 0.43% | +163.49% | Jun 2026 |
| UBS Group AG | 110K | 0.36% | -56.42% | Jun 2026 |
| Westside Investment Management, Inc. | 108K | 0.35% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 106K | 0.34% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 105K | 0.34% | -14.94% | Jun 2026 |
| State Street Corp | 93.4K | 0.30% | -67.90% | Jun 2026 |
| HRT FINANCIAL LLC | 84.4K | 0.27% | 0.00% | Jun 2026 |
| IEQ CAPITAL, LLC | 82.4K | 0.27% | +235.40% | Jun 2026 |
| GSA Capital Partners LLP | 82.0K | 0.26% | 0.00% | Jun 2026 |
| Virtu Financial LLC | 75.2K | 0.24% | 0.00% | Jun 2026 |
| Acadian Asset Management LLC | 71.2K | 0.23% | 0.00% | Sep 2026 |
| Laird Norton Tyee Trust Co | 52.0K | 0.17% | +4.00% | Jun 2026 |
INmune Bio Inc company profile
- Company name
- INmune Bio Inc
- Ticker
- INMB.US
- Exchange
- USA Stocks
- Listed since
- Feb 4, 2019
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 21
- Fiscal year end
- December
- Address
- 225 NE Mizner Blvd., Boca Raton, FL, United States, 33432
- Phone
- 561 710 0512
- Website
- inmunebio.com
About INmune Bio Inc
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
INmune Bio Inc management
5- Mr. David J. Moss M.B.A.President, CEO, Treasurer, Secretary & Director · born 1970
- Mr. Cory Randall EllspermannInterim Chief Financial Officer · born 1973
- Dr. Mark William Lowdell Ph.D.Co-Founder, Chair of Scientific Advisory Board, CSO & Chief Manufacturing Officer · born 1963
- Mr. Daniel Frederick CarlsonHead of Investor Relations · born 1967
- Mr. Joshua S. Schoonover Esq.General Counsel